475086-70-5

Upstream product

• 90401-60-8 5-benzyloxy-1,2,3,4-tetrahydro-naphthalen-1-one 
• 616-38-6 carbonic acid dimethyl ester 
• 28315-93-7 5-Hydroxy-1-tetralone 
• 100-39-0 benzyl bromide 

Downstream Products

• 475086-71-6 5-(benzyloxy)-1-hydroxy-2-(methoxycarbonyl)-1,2,3,4-tetrahydronaphthalene 

Relevant academic research and scientific papers

Solvent-Free Synthesis of Salen Ligands and Pd(II)- and Cu(II)-Salen Complexes: Their Use in the Oxidation of α-Tetralones to α-Naphthols

Racemic trans -cyclohexane-1,2-diamine was allowed to react with eleven aldehydes with different patterns of substitution at the aromatic ring, in the absence of solvent, by manually milling the reagents. The corresponding imines were obtained in moderated to high chemical yields, in only 10 minutes of reaction. A one-pot, two-step preparation of stable complexes of selected imines with Pd(OAc) 2 and Cu(OAc) 2 and the use of these complexes as catalysts in the aromatization of methyl 1-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylate to the corresponding methyl 1-hydroxynaphthalene-2-carboxylates, is also reported.

Copper- versus palladium-catalyzed aromatization of 2-(methoxycarbonyl) tetralones: Synthesis of methyl 1-hydroxy-2-naphthoates

The aromatization of α-tetralones substituted at the β-position by an ester group is reported using either CuI or Pd2(dba)3. In the case of using CuI (10 mol %) as catalyst and Cs2CO3 as base in dioxane, 2-(methoxycarbonyl)-α-tetralones are smoothly converted into the corresponding methyl 1-hydroxy-2-naphthoates at 70 °C under air. Alternatively, Pd2(dba)3 (1.25 mol %) can also be used as catalyst in the presence of K3PO4 as base in toluene also at 70 °C under argon. These are the most straightforward methodologies for the aromatization of these types of α-tetralones. CuI is the catalyst of choice due to higher efficiency, economical and practical reasons.

HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES

The present invention provides a compound which is useful as a PGI2 receptor agonist, and a pharmaceutical composition. The present invention is directed to a pharmaceutical composition comprising a compound represented by the following formula [1]: (R1 and R2 are the same or different and each represents optionally substituted aryl, Y represents N or CH, Z represents N or CH, A represents NH, NR5, O, S, or ethylene, R5 represents alkyl, D represents alkylene or alkenylene, E represents phenylene or single bond, G represents O, S, or CH2, R3 and R4 are the same or different and each represents hydrogen or alkyl, Q represents carboxy, alkoxycarbonyl, tetrazolyl, carbamoyl, or N-(alkylsulfonyl)carbamoyl), or a pharmaceutically acceptable salt thereof as an active ingredient.